Targacept, Incorporated (TRGT)
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Dr. J. Donald deBethizy, Ph.D., CEO/President/Director
200 East First Street
Suite 300
Winston-Salem, NC 27101
US
Map it ![]()
Phone: (336) 480-2100
Fax: (336) 480-2107
Overview
A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics(tm), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system.
Portfolio Articles
-
The Ultimare Cure
The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed.May 12 2008
Press Releases
-
Targacept Reports Third Quarter 2008 Financial Results Nov-06-2008, 04:05PM EST
-
Targacept to Report Third Quarter 2008 Financial Results on November 6, 2008 Oct-30-2008, 08:55AM EDT
News From Around the Web
News
-
Targacept scientists give reports on variety of topics
(Winston-Salem Journal, North Carolina)Nov 21 2008 -
Nov 20 2008
-
North Carolina Biotechnology Center Announces Company Sponsors for New Industrial Fellowship
(BioPharm International)Sep 09 2008
Employees
Number of Employees: 100
Revenue per Employee: $379,128
Top Executives
Dr.Geoffrey C. Dunbar, M.D., Divisional Vice President
Peter A. Zorn, Divisional Vice President/General Counsel/Secretary
Jeffrey P. Brennan, Divisional Vice President
Alan A. Musso, CPA, CFO/Vice President/Treasurer/Assistant Secretary
Dr. William S. Caldwell, Ph.D., Divisional Vice President
Dr.Merouane Bencherif, M.D., Ph.D., Divisional Vice President
Board of Directors
Mark Skaletsky, Chairman of the Board/Director
Peter A. Zorn, Divisional Vice President/General Counsel/Secretary
Julia R. Brown, Director
Alan A. Musso, CPA, CFO/Vice President/Treasurer/Assistant Secretary
Charles A. Blixt, Director
Dr.Errol B. De Souza, Ph.D., Director
Financials
Quarterly
Annual
| Income Statement | 11/2008 | 08/2008 | 05/2008 | 03/2008 |
|---|---|---|---|---|
| Sales | 183 | -281.2 K. | -173.95 K. | -99.06 K. |
| Gross Operating Profit | 3.95 K. | 5.44 Mil. | 4.45 Mil. | 3.66 Mil. |
| Operating Income before D & A (EBITDA) | -8.16 K. | -6.97 Mil. | -6.32 Mil. | -8.38 Mil. |
| Total Income Before Interest Expenses (EBIT) | -7.65 K. | -6.73 Mil. | -5.73 Mil. | -7.6 Mil. |
| Total Net Income | -7.65 K. | -6.8 Mil. | -5.78 Mil. | -7.65 Mil. |
| Basic EPS, Total | -0.31 | -0.27 | -0.24 | -0.37 |
| Diluted EPS, Total | -0.31 | -0.27 | -0.24 | -0.37 |
| BALANCE STATEMENT | 11/2008 | 08/2008 | 05/2008 | 03/2008 |
|---|---|---|---|---|
| Cash and Equivalents | 93.75 K. | 64.37 Mil. | 65.47 Mil. | 53.4 Mil. |
| Total Assets | NA | 106.83 Mil. | 97.53 Mil. | 92.41 Mil. |
| Total Liabilities | 14.23 K. | 14.09 Mil. | 13.59 Mil. | 15.2 Mil. |
| Total Capitalization | 62.26 K. | 72.98 Mil. | 79.23 Mil. | 53.27 Mil. |
| Cash Flow | 11/2008 | 08/2008 | 05/2008 | 03/2008 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | -15.14 Mil. | -6.72 Mil. | 24.84 Mil. |
| Net Cash From Investing Activities | NA | -5.63 Mil. | -13.29 Mil. | -26.29 Mil. |
| Net Cash From Financing Activities | NA | 31.73 Mil. | 32.08 Mil. | 13.11 Mil. |
| Net Change in Cash & Cash Equivalents | NA | 10.96 Mil. | 12.06 Mil. | 11.66 Mil. |
| Income Statement | 2008 | 2007 | 2006 |
|---|---|---|---|
| Sales | -191.74 K. | -363.67 K. | -322.25 K. |
| Gross Operating Profit | 11.77 Mil. | 27.9 Mil. | 1.5 Mil. |
| Operating Income before D & A (EBITDA) | -30.86 Mil. | 417.23 K. | -29.14 Mil. |
| Total Income Before Interest Expenses (EBIT) | -27.93 Mil. | 2.18 Mil. | -28.77 Mil. |
| Total Net Income | -28.07 Mil. | 2.1 Mil. | -28.99 Mil. |
| Basic EPS, Total | -1.42 | -0.09 | -153.54 |
| Diluted EPS, Total | -1.42 | -0.09 | -153.54 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 |
|---|---|---|---|
| Cash and Equivalents | 53.4 Mil. | 41.74 Mil. | 24.85 Mil. |
| Total Assets | 92.41 Mil. | 78.85 Mil. | 25.74 Mil. |
| Total Liabilities | 15.2 Mil. | 8.95 Mil. | 5.21 Mil. |
| Total Capitalization | 53.27 Mil. | 65.81 Mil. | -161.07 Mil. |
| Cash Flow | 2008 | 2007 | 2006 |
|---|---|---|---|
| Net Cash From Continuing Operations | 24.84 Mil. | -9.89 Mil. | -26.25 Mil. |
| Net Cash From Investing Activities | -26.29 Mil. | -13.27 Mil. | -250.25 K. |
| Net Cash From Financing Activities | 13.11 Mil. | 40.05 Mil. | -1.73 Mil. |
| Net Change in Cash & Cash Equivalents | 11.66 Mil. | 16.89 Mil. | -28.22 Mil. |
News Volume
31 days volume
100%
80%
60%
40%
20%
0
October
November
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.



